Preclinical News and Research

RSS

Blocking Epac1 protein slows lung fibrosis in preclinical models

Researchers at the Icahn School of Medicine at Mount Sinai and collaborators have identified a previously overlooked protein, Epac1, as a key driver of idiopathic pulmonary fibrosis (IPF), a chronic and progressive lung-scarring disease.

15 Jul 2025

New UAB-developed gene therapy for ALS receives orphan drug designation

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to a new gene therapy for Amyotrophic Lateral Sclerosis (ALS) developed at the Universitat Autònoma de Barcelona and licensed to the U.S. company Klotho Neurosciences, Inc.

15 Jul 2025

Pathogenic mechanisms of Fusobacterium nucleatum in colorectal cancer and emerging therapies

In recent years, the regulatory role of the gut microbiota in the initiation and progression of colorectal cancer (CRC) has attracted growing attention. Among the key microbial contributors, Fusobacterium nucleatum (Fn) has been identified as a critical pathogenic factor in CRC.

12 Jul 2025

CMD-OPT model enables discovery of potent and selective RIPK2 inhibitor for acute liver injury

This new article publication from Acta Pharmaceutica Sinica B, discusses how a CMD-OPT model enables the discovery of a potent and selective RIPK2 inhibitor as preclinical candidate for the treatment of acute liver injury.

12 Jul 2025

Exploring the roles of orphan nuclear receptors in MASLD pathogenesis

Metabolic dysfunction-associated steatotic liver disease (MASLD), affecting approximately 30% of the global population, represents a spectrum of liver disorders ranging from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, and cirrhosis.

12 Jul 2025

Monoclonal antibody delivered through the nose blocks hay fever in mice

Approximately 40% of the European population are allergic to pollen, and their symptoms cause an estimated loss of 100 million school- and workdays every year.

11 Jul 2025

Fasting triggers neuroprotective changes that could delay dementia

Intermittent fasting could be a neuroprotective strategy, improving gut-brain axis function and reducing inflammation linked to neurodegenerative diseases.

11 Jul 2025

Hydrogels could be key to safer, smarter cancer drug delivery

Hydrogels could revolutionize cancer treatment by facilitating targeted drug delivery, reducing adverse effects, and enhancing therapeutic effectiveness.

11 Jul 2025

Does pomegranate seed oil really help your heart? New research weighs the evidence

This review explores the potential of punicic acid in pomegranate seed oil as a nutraceutical for cardiovascular health. While preclinical evidence is promising, robust human trials are needed to confirm its benefits.

10 Jul 2025

How hydrogels are shaping the future of targeted cancer drug delivery

A large-scale bibliometric analysis maps global research on hydrogels as next-generation drug delivery systems for cancer therapy. The study highlights emerging trends, key contributors, and future directions to advance precision medicine in oncology.

10 Jul 2025

Psilocybin may have potential to revolutionize anti-aging therapies

As revenues from the anti-aging market-- riddled with hope and thousands of supplements–– surged past $500 million last year, Emory University researchers identified a compound that actively delays aging in cells and organisms.

9 Jul 2025

FDA-approved drugs can help enhance the safety of nanomedicines

An international study led by researchers at the University of Colorado Anschutz Medical Campus has identified a promising strategy to enhance the safety of nanomedicines, advanced therapies often used in cancer and vaccine treatments, by using drugs already approved by the FDA for unrelated conditions.

9 Jul 2025

UCLA researchers discover new way to prevent immunotherapy-induced type 1 diabetes

A team of researchers at the UCLA Health Jonsson Comprehensive Cancer Center has identified a potential new strategy to prevent, and even reverse, immune checkpoint inhibitor–induced type 1 diabetes, a rare but life-threatening side effect of cancer immunotherapy, using an existing class of autoimmune drugs.

8 Jul 2025

Aspartame triggers genetic changes tied to glioblastoma severity

Study shows aspartame affects gut microbiome and gene expression in glioblastoma, highlighting potential links to cancer progression and treatment strategies.

8 Jul 2025

Landmark discovery reshapes understanding of key cancer protein MCL-1

Landmark research on MCL-1, a critical protein that is an attractive target for cancer drug development, helps explain why some promising cancer treatments are causing serious side effects, and offers a roadmap for designing safer, more targeted therapies.

8 Jul 2025

Corticosteroids may reduce effectiveness of immunotherapy in lung cancer

Corticosteroids, a commonly prescribed medication to alleviate cancer-related symptoms for non-small cell lung cancer patients treated with immunotherapy, are the main reason certain immunotherapies may fail in treating the disease, according to new research by Keck Medicine of USC.

7 Jul 2025